Young women who become pregnant while in remission from Hodgkin lymphoma are not at increased risk of cancer recurrence, according to a study published in the Journal of Clinical Oncology.
Palliative care focuses on preventing, managing, and relieving the symptoms of cancer and the side effects of cancer treatment. It also provides comprehensive support to people living with cancer and their family, friends, and caregivers. At Mount Sinai Medical Center in New York, doctors are trying an innovative new approach to caring for patients with advanced cancer who need radiation therapy, typically for cancer that has spread. In this approach, patients are evaluated by both radiation oncologists and specialists in palliative care.
A prospective study of more than 100,000 Americans suggests that consuming citrus fruit, specifically whole grapefruit and orange juice, frequently may increase one’s chance of developing melanoma. However, experts stress more research is needed and caution against making any dietary changes based on this study at this time.
Recently, researchers found that nivolumab (Opdivo) either given as a single treatment or in combination with ipilimumab (Yervoy) is more effective than treatment with ipilimumab alone for people with advanced melanoma.
A new study provides clarification on the best time for patients to receive lymph node surgery for early-stage oral cancer.
In a recent study, researchers found that radiation therapy to the whole brain after radiosurgery for cancer that has spread to the brain causes more thought and memory problems than just radiosurgery. Even though the additional radiation therapy controlled the cancer’s growth, it did not lengthen patients’ lives.
A recent analysis of information from more than 34,000 children who participated in the Childhood Cancer Survivor Study shows that modern cancer care is reducing deaths from cancer and long-term side effects.
According to a recent small study, the drug daratumumab may work well as a treatment for multiple myeloma after other treatments have not worked.
A large phase III study has found that a new targeted therapy, called palbociclib (Ibrance), delayed the growth and spread of advanced hormone receptor-positive breast cancer by roughly five months when combined with the standard hormonal therapy fulvestrant (Faslodex). This combination could become a new treatment option for women with hormone receptor-positive, HER2-negative breast cancer that has spread to other parts of the body.
A large clinical trial suggests that anastrazole (Arimidex) may be a new option for preventing breast cancer after treatment for ductal carcinoma in situ (DCIS). DCIS is a non-invasive type of breast cancer. DCIS can usually be eliminated with a lumpectomy followed by radiation therapy. However, women with DCIS are at increased risk for developing invasive breast cancer in the same or opposite breast.